Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tarsus Pharmaceuticals (TARS) EBITDA Margin (2021 - 2025)

Tarsus Pharmaceuticals has reported EBITDA Margin over the past 5 years, most recently at 5.46% for Q4 2025.

  • Quarterly results put EBITDA Margin at 5.46% for Q4 2025, up 2960.0% from a year ago — trailing twelve months through Dec 2025 was 14.67% (up 4839.0% YoY), and the annual figure for FY2025 was 14.67%, up 4839.0%.
  • EBITDA Margin for Q4 2025 was 5.46% at Tarsus Pharmaceuticals, up from 10.39% in the prior quarter.
  • Over the last five years, EBITDA Margin for TARS hit a ceiling of 31.04% in Q1 2021 and a floor of 4393.79% in Q4 2021.
  • Median EBITDA Margin over the past 5 years was 64.72% (2024), compared with a mean of 735.52%.
  • Peak annual rise in EBITDA Margin hit 425716bps in 2022, while the deepest fall reached -378577bps in 2022.
  • Tarsus Pharmaceuticals' EBITDA Margin stood at 4393.79% in 2021, then skyrocketed by 97bps to 136.63% in 2022, then plummeted by -135bps to 320.4% in 2023, then soared by 89bps to 35.06% in 2024, then soared by 84bps to 5.46% in 2025.
  • The last three reported values for EBITDA Margin were 5.46% (Q4 2025), 10.39% (Q3 2025), and 19.86% (Q2 2025) per Business Quant data.